Biotech Values

[mcbio]

To my untrained eye, these look like very good results. I appreciate comments from the more knowledgeable posters about oncology drugs.

Would just say that the big caveat is they are comparing to historical control data; doesn't mean a whole lot until we get controlled data. On that note, I believe CLDX said we would get data in 2H13 from a controlled Phase 2 of rindo in recurrent glioblastoma in combo w/Avastin vs. Avastin+KLH control. Think this is where we get an initial true read on the drug's activity.